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Human-in-the-loop intelligence augmentation (IA) 
methods combined with visual analytics (VA) have the 
potential to provide additional functional capability 
and cognitively driven interpretability to Decision 
Support Systems (DSS) for health risk assessment and 
patient-clinician shared decision making. This paper 
presents some key ideas underlying the synthesis of IA 
with VA (IA/VA) and the challenges in the design, 
implementation, and use of IA/VA-enabled clinical 
decision support systems (CDSS) in the practice of 
medicine through data driven analytical models. An 
illustrative IA/VA solution provides a visualization of 
the distribution of health risk, and the impact of 
various parameters on the assessment, at the 
population and individual levels. It also allows the 
clinician to ask “what-if” questions using interactive 
visualizations that change actionable risk factors of 
the patient and visually assess their impact. This 
approach holds promise in enhancing decision 
support systems design, deployment and use outside 
the medical sphere as well. 
1. Introduction  
Decision support systems (DSS), clinical decision 
support systems (CDSS) included, are designed to 
provide guidance to decision makers as they analyze 
new situations and require assistance in assessing 
situations and in answering “what if” type questions. 
CDSS do so mostly by recording existing knowledge 
and processing techniques, sometimes even applying a 
straightforward rule-based dataset that applies current 
thinking to new data. Those objectives are not new [1], 
dating back to Ledley and Lusted [2]. Sheppard and 
Kouchoukos [3] added automated rules and tests to 
CDSS architecture, resulting in a consensus of the 
need to analyze patient data to create case-specific 
advice [4]. More recently, machine learning has also 
been added [5], a necessity considering the size and 
complexity of healthcare datasets [6]. CDSS currently 
support many medical fields including patient care at 
the bedside, medical imaging, pharmacology, 
pharmacogenomics, and pathology, among others [7].  
CDSS have been shown to improve medical best 
practices [8], increase quality of care and patient safety 
[9], reduce medical errors [10], and support diagnosis 
[11]. Indeed, CDSS that assess renal function, 
pregnancy complications, duplicate order entry, drug 
allergy, and drug recommendation, have a long history 
in reducing rates of medical errors [12], with early 
studies on CDSS claiming decrease of 12.7% decrease 
in total charges and a 0.9 day decrease in length of stay 
[13]. Based on the experiences of some leading, large, 
highly computerized, and internationally recognized 
medical centers, CDSS are under-utilized if used at all 
for diagnosing patients [1].  
Apart from reducing errors, the objective of 
CDSS is to improve clinicians’ decision-making 
processes and provide medical insights at the point of 
care [14], a hard to achieve objective [7]. In part, that 
is because designing a medical treatment path often 
requires real-time, interactive processing of patient 
data by the clinicians involved. That interactive 
processing is necessary to attain more accurate clinical 
predictions of what a course of treatment may entail 
based on the analysis of many other patients’ data 
while considering a multitude of varying parameters. 
Such interactive processes could also decrease the 
incidence of errors. Errors are a major obstacle to the 
voluntary adoption of CDSS by physicians [7]. 
Moreover, and perhaps contributing to that error rate, 
are patients with multi-morbid conditions.  
Interactive CDSS are at a rather extreme point in 
current classifications. Belard & Buchman [1] 
suggested that CDSS can be classified into 
knowledge-driven, rule-based support systems and 
data-driven, probability analysis support systems. 





Rule-based systems include CDSS that alert about 
medication hazards [14] and drug interactions based 
on existing guidelines (even if these ignore patient-
specific situations) [10]. Closer to probability analysis, 
CDSS are systems such as those that support dementia 
diagnosis by applying reasoning strategies, some even 
based on ambiguous and incomplete information [15, 
16], diagnose prostate cancer [11] and predict whether 
a person is a carrier of toxic gene mutations that cause 
breast cancer [12]. Adding the degree of user 
interaction, Liedgren & Elvhage [17] classified DSS 
on a grid with descriptive or normative on one axis, 
and static or user interactive on the other (Figure 1). 
Interactive CDSS with a data-driven probability 
analysis engine fall into the top of the left quadrant 
being designed to address very complex medical 
conditions without relying on a set of rules only. 
 
Figure 1. DSS classification based on [17] 
1.1. Barriers to CDSS implementation 
Among the major obstacles to successful 
deployment of CDSS are perceptions that the CDSS 
obscures physician autonomy and obligation and that 
the recommendations are insufficiently relevant and 
current [1]. The result is a lukewarm attitude towards 
current CDSS because it is perceived that the analysis 
and the rules behind the CDSS are too simple, and so 
physicians, specifically experts, are reluctant to rely on 
the CDSS because it makes it seem, wrongly, that their 
profession can be automated. Simple CDSS that 
record existing rule-bases just do not provide a 
convincing incentive to potential adopters. However, 
when the decision is very complex and the analysis is 
not perfectly clear to the cardiologists, then using the 
CDSS is too risky. One way of overcoming this 
conundrum is by allowing the design and subsequent 
interaction with the CDSS to be user-centered [18]. 
This also increases its perceived utility [19].  
An alternative approach, examined in this study, 
is to replace the DSS rule-base with a dynamic AI-
based, intelligence augmentation and visual analytics 
that provides additional functional capability and 
cognitively-driven interpretability to DSS-enabled 
risk assessment. This AI-driven, visually augmented 
approach stands in contrast to typical DSS that freeze 
knowledge at the point where its rule-base has been 
created, potentially resulting in the dangerous 
ossification of knowledge in a rapidly changing 
context. What is needed is a dynamic support system 
that is not based on a rule base alone, but rather a 
system that lets the human expert explore options 
based on a real-time analysis of existing relevant data 
without being forced into a rigid pattern of thought that 
had been prevalent when the DSS or CDSS was 
created. Such a system could allow decision makers to 
consider “what if” questions dynamically and allow 
any kind of analysis that existing data had measured. 
A dynamic visual representation of data analysis 
results is called Visual Analytics (VA), and is 
currently perceived as the preferred mode of informing 
users about complex results [20]. VA can be static or 
collaborative, with the latter allowing users to harness 
their expertise to improve the system’s performance. 
Thus, the computer and user work in collaboration, 
with each partner contributing their strengths and 
unique capabilities: the computer in analyzing 
complex, big data and creating visual data 
presentations, and the user in pinpointing the search 
and analysis to points of interest, employing the 
holistic view, which is part of human expertise that a 
computer lacks. This approach is termed Intelligence 
Augmentation (IA) [21]. 
We describe a CDSS prototype that is composed 
of an AI-based back-end analysis engine for predictive 
analytics and results visualization, and a VA-IA based 
front-end component, for the user and computer to 
interact with and collaborate in a human-in-the-loop 
format, for optimal decision making. The AI-based 
engine dynamically and without resorting to a 
predefined rule-base analyzes all the medical tests, 
diagnostics, prognosis, and treatments, including the 
ICD codes of thousands of patients with the same 
overall medical condition as observed over many 
years. (ICD is the International Statistical 
Classification of Diseases and Related Health 
Problems. It was created and is continuously updated 
by the World Health Organization (WHO) as a 
classification system. More about ICD can be found at 
https://www.who.int/classifications/icd/en/).  
In the next two sections, we briefly describe the 
IA and VA concepts. 
1.2. Intelligence augmentation (IA) 
With the prevalence of large amount of data and 
ubiquity of computing power, we recently see more 
tasks being performed by computers, profoundly 
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changing the modern way of life at work and beyond 
[22]. The promise of AI has also given rise to the 
growing debate on whether a thinking machine is 
possible and whether the notion of such a machine 
provides a suitable model of the human mind [23]. 
Specifically, problems in artificial intelligence are 
often framed in terms of matching or surpassing 
human performance [24]. While there is an increased 
concern that smart machines may replace many 
humans in decision making, current evidence is that, 
with greater computational information-processing 
capacity and an analytical approach, machines can 
amplify human cognition when addressing 
complexity, whereas humans offer a more holistic, 
intuitive approach in dealing with uncertainty in 
decision making [25]. This new concept is termed 
Intelligence Augmentation (IA), in contrast to human-
computer interaction (HCI) where man and machine 
are considered separate entities [26]. 
IA focuses on building systems that allow humans 
and machines to work together, as opposed to AI, 
which is focused on building intelligence in machines. 
Intelligence Augmentation provides an efficient 
theoretical framework for understanding what humans 
can accomplish and how artifacts and tools can be 
designed and evaluated to empower human beings and 
to alter tasks [27]. 
The goal of IA, in the context of this study, is to 
use computational systems to help physicians in the 
decision making process by means of an ongoing 
human-machine dialogue [28]. The belief underlying 
this human-machine collaboration is that it potentially 
allows the humans to gain the time to concentrate on 
other parts of the process and thereby expanding their 
perspectives and augmenting their intellect [29]. IA 
has been recently proposed as assisting clinical 
assessment workflow, to sequentially augment 
physician assessment of patients’ symptoms, while 
integrating their socio-demographic determinants and 
heterogeneous biological measures to accurately 
predict treatment outcomes using machine learning 
methods [30]. Yet, cumbersome human-computer 
communication and challenging user interfaces pose 
barriers to wide utilization of these IA platforms in 
highly stressed and time-constrained clinical settings. 
Recent research has suggested interactive 
visualizations leveraging advanced analytics, which 
are yet relatively easy to use and comprehend, as a 
plausible human-computer communication platform 
[31, 32] suitable for environments such as clinical care 
delivery.  
1.3. Visual analytics (VA) 
Visual analytics (VA) combines computational 
analysis and interactive visualization-based user 
interfaces to support analytical reasoning and human 
cognition, incorporating disciplines including 
cognitive science, data mining and machine learning 
[33]. This enables interactive, analytical interpretation 
of very large and complex datasets through the 
integration of human intuition and machine learning 
[20, 34, 35]. VA is especially applicable where the 
data are too large, and the decisions too complex, for 
purely visual methods, and therefore require data 
processing and mining capabilities in exploratory 
setting. This necessitates an interdisciplinary approach 
[29]. VA is particularly useful when dealing with 
multivariable items, aka “dimensions” that are sourced 
from multiple systems, are sparsely populated, and 
might even be of questionable quality. 
Comprehending multi-dimensional information is 
difficult, known as ‘the curse of dimensionality’ [36]. 
Health data is an example of multivariable, multi-
sourced data. Policy and decision makers in healthcare 
have long valued the capacity of healthcare 
information to improve clinical decision making by 
assuming that such data, if available to the right people 
in an appropriate format and at the right time, could 
significantly drive healthcare effectiveness and 
efficiency [37]. It is therefore not surprising that many 
recent studies have examined the application of VA in 
the healthcare domain [38-40].  
2. Methods  
2.1. CDSS requirements analysis 
Requirements for the CDSS design were gathered 
from a thorough literature survey and interactions with 
clinical experts that resulted in the development of an 
early prototype (not displayed due to space 
limitations). This prototype was then demonstrated to 
experts in diabetes mellitus and heart disease [31], 
whose comments were used for the generation of the 
second version of the prototype which is the focus of 
this study. This version was reviewed by three 
cardiologists, who saw a demonstration of the 
prototype using patient data from their own setting and 
commented on the displayed features. 
2.2. Data set for the AI-driven engine 
The research dataset, focused on the 
cardiovascular condition, was obtained from the Sheba 
Medical Center, which is the largest hospital in Israel, 
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located in the center of the country [41]. It is an 
extensively computerized hospital, where an 
integrated EHR system is used in the Emergency 
Department (ED) and all inpatient departments, fully 
replacing paper-based medical records. In recent 
years, Sheba has established a research-focused data 
warehouse that collects data from the various 
information systems installed in the hospital. Patient 
socio-demographic data is obtained from the Israel 
Population Registry system and integrated into the 
EHR. Each patient admitted to the hospital, via the ED 
or otherwise, who is diagnosed with a cardiovascular 
condition as a primary diagnosis, has their data 
uploaded to the data warehouse. All patient 
information is then retrieved from the other systems 
using the individual’s unique national ID available in 
the Israeli Population Registry. This unique identifier 
allows accurate location and integration of patient 
data. We removed variables with more than 20% 
missing values based on clinical judgment and used 
the Predictive Mean Matching imputation method [42] 
with the mice package in R [43] to impute missing 
values in key attributes that could not be eliminated 
from consideration. Diagnoses were coded based on 
the ICD-9 standard. The resulting dataset included 
10,763 patients who visited the Sheba Medical Center 
between 2010 and 2017 and were diagnosed with 
Congestive Heart Failure (CHF) as the primary 
diagnosis. Each patient record included 211 attributes. 
2.3. The feature selection process 
Two senior cardiologists selected 30 features they 
considered most effective to predict 30-day 
readmission or 30-day mortality based on extant 
scientific knowledge and local practices and 
outcomes. Next, we evaluated multiple feature 
selection criteria and identified the Information Gain 
(IG) [44] method to select a set of 30 features, to 
investigate if the method may delineate features not 
commonly selected by cardiologists. Information Gain 
(IG) favors splits with small counts but many unique 
values.  
The human and machine generated feature sets 
were then merged to a larger feature set consisting of 
45 variables. This was evaluated by two different 
experts (senior cardiologists), to mark those features 
they regarded as most important for mortality and 
readmission (two separate sets), respectively. We 
tested the lists for inter-rater agreement using Cohen’s 
Kappa [45], resulting in moderate to poor agreement 
among the raters (0.688 for mortality and 0.474 for 
readmission, before adjusting for chance agreement). 
Next, we extracted the features disagreed upon and 
returned to the same physicians two weeks after the 
first session, asking them to re-rate only those items, 
without indicating prior choices. This second round 
yielded high agreement (0.893 and 0.938 for 
readmission and mortality, respectively, and 0.777 and 
0.858 after adjusting for chance agreement), resulting 
in a final set of 29 variables for mortality and 28 
variables for readmission. We termed the sets 
“Human-Machine Collaborative” sets. 
3. The new CDSS approach 
A key characteristic of the approach utilized by 
the new CDSS is that it allows the clinician to apply a 
data-driven, exploratory approach. This analysis 
encompasses data discovery by assessing patterns in 
the medical records of the other patients to inform the 
decision maker. This is a bottom-up approach, in 
contrast to the objectives of some CDSS that attempt 
to enforce policy and standardization of decision 
making through a policy driven, top-down process. 
The new CDSS is about empowering the clinicians 
with additional visual tools that can address new topics 
and questions, supported in the backend by AI, 
allowing the clinician to review medical records of 
other patients that inform the visual presentation. 
Moreover, as the visual presentation displays numbers 
based on predictive analytics, the recommendation is 
mostly quantitative and leaves the actionable 
interpretation to the clinician. For example, showing 
the probability that changing the systolic blood 
pressure of the patient by so many units will change 
the likelihood of expected mortality by so many 
percentage points. This type of analysis can, providing 
the dataset it is based upon is large enough, also allow 
answering many complex what-if questions 
concurrently, allowing interaction analyses. For 
example, a physician may ask about the result of both 
reducing systolic blood pressure by 10% but only 
among patients with a certain condition (including one 
or more existing comorbidities). This ad hoc type of 
investigation is unique to current clinical decision 
making due to the availability of highly granular data 
on many patients collected as part of routine medical 
practice and applies without relying on existing rules 
and research. The approach also allows studying 
patient-reported adverse reactions that have not yet 
been identified in the literature, and hence are absent 
from any rule-base a CDSS could possibly apply. This 
ad-hoc and evidence-based analysis also allows an 
investigation of the what-if questions in the context of 
a specific demographic or social determinant, such as 
women only or living in a particular neighborhood 
type. Such an assignment of numeric values to the risk 
associated with the co-occurrence of medical 
conditions, tests, and treatments, could also open the 
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opportunity of adding hypothesis testing and complex 
multilayer path analysis models. This ability to test 
hypotheses is another characteristic that sets this 
CDSS approach in a new direction. Moreover, this 
approach could provide insights also about multi-
morbid conditions that have not yet been incorporated 
into existing CDSS models, but about which there is 
data available from other patients, past and present, 
with an equivalent profile.  Being exploratory also 
means that the proposed CDSS approach could reveal 
data-derived previously unknown patterns, and that 
these patterns may vary across populations.  
Basically, the new approach stands in contrast to 
existing CDSS approaches that are beneficial in 
training based on known medical case-studies and 
guidelines, and in enforcement of rules as well as 
testing for mistakes such as drug interactions. 
However, based on the extant literature, and on our 
preliminary interviews with cardiologists to whom the 
new CDSS has been demonstrated, the approach of 
common CDSS is generally too rigid and holds limited 
benefits to them once the rules are known and training 
is over. In contrast, the new CDSS approach, because 
it is about empowering the decision maker, rather than 
checking or prescribing their actions, was accepted 
enthusiastically. That is important also because one of 
the major holdbacks in the adoption of healthcare IT is 
the reluctance of clinicians to adopt the new IT and its 
organizational solution, partly because it infringes on 
rather than augments their capabilities [46]. There 
needs to be a viable value proposition in new IT if it is 
to be adopted. The intelligence augmentation enabled 
CDSS, the easy-to-use visual presentation, and its AI-
based analysis of the population provides such a value 
proposition. That value proposition is increased by the 
ability to examine specific patient profiles and where 
the patient fits into each such profile, such as by 
varying demographics, social determinants and 
clinical history parameters. Applying such a data-
driven exploratory approach to AI augmented decision 
making, we extended an existing prototype, developed 
by one of the co-authors and collaborators in a prior 
study [31], to include additional requirements for a 
visual CDSS prototype and presented it to 




4.1. The CDSS functions  
Figures 2 to 7 show the pertinent aspects of this 
CDSS as it was demonstrated to cardiologists on a 
subset of the Sheba CHF data. Creating and managing 
appropriate expectations is a crucial first set in this 
process. To date, many cardiologists among those we 
interviewed were disappointed by other approaches to 
CDSS that had solidified and verified current best-
practices, tested drug interactions, workflows, and 
billing procedures. Those aspects are beyond doubt 
very important in managing standard processes and 
enforcing quality controls, many of which are 
mandated. The current CDSS approach is not intended 
to replace those processes, but, rather, to build on top 
of those processes another layer to augment their 
clinical decision-making capability. The initial screen, 
Figure 2, is intended to set those expectations in place. 
Based on those expectations, the cardiologist is 
then provided with tools to run descriptive analysis on 
the data. This is not the core contribution of the new 
CDSS, but it serves an important purpose of increasing 
the transparency and explainability of the CDSS, as 
well as exploration of the population under 
investigation. Figure 3 is an example of one such 
variable, age. This aspect is not unique or new. It is 
merely showing that the population at hand is indeed 
quite elderly, as expected, although the number of 
relatively younger patients is not negligible. Thus, a 
user can decide to investigate only a sub-population of 
older or younger patients. The data show that CHF 
increases gradually with age, reaching the peak 
number of people diagnosed with it in this sample to 
be between 84 and 87 years of age. The fact that this 
is aligned with common medical knowledge may 
strengthen the cardiologists’ trust in the system. For 
this purpose, this CDSS allows having all prediction 
performance scores available to the decision makers 
(e.g, Precision, Recall, Confusion matrix and 
Accuracy) on any selected population, so that a user 
who is knowledgeable on predictive analytics can 
assess the predictive power of the system.  
The next typical stage in data analysis is to run 
multivariate analyses. The simplest of these is a 
Pearson correlation, showing the linear correlation 
coefficients among pairs of terms in the data, a 
prerequisite for good feature selection. The matrix 
shows the correlations among the variables or factors 
through a heatmap where the darker the blue cell, the 
higher the positive correlation with the target variable; 
the darker the red cell, the higher the negative 
correlation. Heatmaps are a standard tool to visualize 
such correlations and allow a quick eyeballing of the 
data to identify correlations of most interest. As 
evident in Figure 4, most factors are not highly 
correlated, indicating that each factor indeed 
contributes independently to the risk prediction. The 
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correlation coefficients are listed in the table next to 
the correlation graph for easy access and verification. 
 
Figure 2. Home page with a simple menu bar and 
short system description 
 
Figure 3. Data exploration  
 
Figure 4. Correlation matrix and heatmap 
Once the data is reviewed and feature selection 
validated, statistical and machine learning methods are 
used to build the risk assessment models [31]. Figure 
5 displays the results of applying these methods to a 
subset of the Sheba data since the interpretation and 
explainability value of visualization is reduced when 
large amounts of data is compressed into a small 2-d 
display. The figure includes several components to be 
noted, such as the scatter plot in the center of the 
graph, the circumscribing circle with the features, the 
methods associated with the x and y axes, the 
boundary line separating the risk dimension, and 
others.  
The circumscribing circle shows the 
factors/features/variables included in the current 
analysis, each one positioned by the algorithm in the 
quadrant where it is most significant. These risk 
factors, or features, are shown in blue, whereas those 
that the user selected to monitor are shown in pink. 
The larger the circle, the more weight that feature has 
in determining the positive or negative risk level. The 
position of that feature on the x and the y axes is 
derived based on the two analytical methods the CDSS 
applies. The pattern shown in the circumscribing circle 
in Figure 5 is the combination of two dimensionality-
reduction methods: principal component analysis 
(PCA) and Fisher’s Linear Discriminant Analysis 
(LDA) [31].  
 
 
Figure 5. Population view, filter slider on the right 
hand side, patient details displayed while 
hovering over an individual patient 
A PCA calculates an orthogonal transformation of 
the original data matrix into principal components so 
that features in the original data that are highly 
correlated with each other will be highly associated 
(and hence correlated) with the same principal 
component. Each principal component is the sum of 
all the features with a weight associated with each 
feature for each principal component. These weights 
are estimated to maximize the level of explained 
variance. Each principal component is accordingly a 
latent variable, or high-level abstraction, that 
represents the features that combine to create it. 
Features may have high weights on more than one 
principal component, suggesting that the same feature 
may contribute highly, with a larger weight, to more 
than one latent variable. As a result, a PCA combines 
the original data points by how close the features 
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expressed in those data points are to each other on a 
set of data derived principal components, so that 
features that have a high weight for the same principal 
component are treated as if they represent the same 
latent construct. The PCA algorithm constructs as 
many principal components as there are features but 
retains only as many as instructed, allowing data 
reduction. Data reduction means that only a few 
abstract latent variables are retained out of the many 
features that combine to create them. As a result, rather 
than having many features, it is their shared 
abstractions, principal components, that are retained. 
In this analysis, we took only the first principal 
component. This principal component has the most 
variance associated with it. The position of the feature 
on this first principal component is shown graphically 
as its position on the x axis.  
An LDA runs a different process to group the 
features. LDA is a machine learning algorithm that 
identifies the best linear combination of independent 
variables (predictors, in this case these are the 
features) that predicts the classification value of one 
dependent variable (in this case, the health risk level). 
While a PCA optimizes the estimation of as many 
principal components as instructed without regard to 
the classification of the values in each component, an 
LDA is optimized to classify one dependent variable 
into one or many classes. The LDA values of each 
feature are shown on the y axis. These are the risk 
levels. The combination of a PCA and LDA allows the 
contrasting of two methods: a PCA that seeks to group 
features by how correlated they are to each other, and 
an LDA that groups them based on how well they 
predict an explicit criterion (in this case, risk of death 
or readmission). This method is based on existing 
functionality [31]. 
The red and green dots in the population view 
(Figure 5) show the scatter plot of risk distribution of 
actual patients within that data induced pattern of 
PCA-based x axis and LDA-based y axis values. Red 
circles are patients with higher risk, green with lower 
risk. The further the patient is from the x axis, the 
higher or the lower that risk is. Hovering the cursor 
over a specific patient circle will open a popup box 
with some details about that patient. That popup box 
shows the patient ID in the dataset, PCA and LDA 
values, a derived textual classification of risk level 
based on the LDA, and a measure of statistical 
influence. This population view presents the overall 
profile of what determines a feature of interest, in this 
case that is risk level, as a function of other features of 
interest, and the position of each data point, in this case 
that is each patient, in that classification scheme. The 
slide on the right-hand side of the screen allows the 
user to filter out the population into a sub-group, based 
on risk level. Thus, the cardiologist can, for example, 
filter out low risk patients, and display only the 20% 
highest-risk patients, for deeper examination. This 
feature is part of the interactive user interface.  
Clicking on a patient circle in Figure 5 opens a 
new screen with details about that specific patient. The 
selected patient’s features are shown as a black dot in 
the left pane, and its details in the right pane. The user 
can then select specific features to monitor for this 
patient, which are displayed in the right-hand side of 
the screen in either graphical or table display. The 
graphical visualization shows the values of the 
features for this specific patient, and how they relate 
to the normal range. Thus, in Figure 6, for patient 
number 96 who is at high risk for mortality within 30 
days, the sodium level in the blood is very high, 
whereas the ejection fraction (ECHO EF) is very low, 
as are the systolic and diastolic blood pressure (SBP 
and DBP, respectively). 
 
Figure 6. Patient view 
The two previous screens allowed an analytics-
guided understanding of the population and a specific 
patient’s risk profile as selected by the user. The next 
stage in the analysis is to show if and how an evidence-
based intervention can reduce the patient’s risk level. 
Figure 7 demonstrates this approach graphically. The 
user can change the values of actionable features to 
those achieved after medical and/or behavioral 
intervention. For example, appropriate diet and 
medication can reduce the sodium level and improve 
SBP and DBP. When the desired values are reached, 
the patient’s likelihood to die will decrease as shown 
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by the “new” red bubble in Figure 7. (The “old” red 
bubble is retained for reference.) This can inform the 
clinician about the effectiveness of a specific 
intervention and serve as an educational and 
motivating tool for clinician-patient shared 
understanding and decision making. 
 
Figure 7. Intervention view: old and new risk 
levels displayed reflecting the potential of a 
successful intervention 
 
The core of the additional analyses enabled by the 
proposed CDSS approach is shown in Figures 5 to 7. 
The first part of that AI augmentation approach is to 
visually show the whole patient cohort as a scatter plot, 
where each dot indicates a patient. The dot is placed 
high or low along the vertical axis – the higher the dot, 
the higher the patient likelihood to die within 30 days 
post discharge (in this example) relative to the cohort. 
Patients placed below the horizontal axis are low-risk 
ones, colored green, while those placed above the 
horizontal axis are high-risk, colored red. Patients are 
spread along the horizontal axis based on factors 
affecting their risk level. Thus, patients with a similar 
risk level, who are placed far from each other, 
significantly differ by their risk factors. The 
dimensionality reduction method implemented in this 
approach performs well in comparison to other widely 
used machine learning methods and evaluated on a 
subset of the Sheba data [47].   
4.2. Cardiologists comments and survey  
A senior cardiologist was involved in the CDSS 
design by providing insights about important functions 




usability using the SUS1. Two additional cardiologists 
(C2 and C3) completed the SUS after attending a 
demonstration of the prototype. SUS is a common tool 
used to assess the perceived usability of a 
computerized system. C1 generally expressed a 
positive assessment of the CDSS and the likelihood of 
his adopting such a system. His main comments 
included recommendations to focus on actionable 
factors affecting patients’ risk, allow the user to add 
factors, automatically provide the normal range of 
factors, and indicate a patient’s risk level as a box plot 
with confidence intervals. He likewise suggested that 
the intervention view can be useful for patient 
education. Cardiologist C2 mainly suggested slight 
modifications to enhance the system’s usefulness and 
ease of use, yet generally approved of the AI-VA-IA 
approach. 
C3 thought positively of the general idea of such 
a CDSS, indicating that this system could assist her in 
gleaning important patient information much faster, 
but needed additional time for further investigation. 
She also suggested that for optimal assimilation into 
the routine clinical process, the system should be 
integrated into the patient’s health record and accessed 
upon the click of a button. The cardiologist would then 
be able to enlarge it to a full-screen display, and 
analyze the patient’s relative risk, as well as simulate 
the intervention results in terms of reduced risk.  
Although more evaluators are warranted, the SUS 
analysis primarily indicated that the respondents 
agreed about their intention to use the system, which 
is the strongest predictor of actual use in all IT 
adoption theories [48]. They also perceived the system 
as easy to use and were quite positive about its 
usefulness. Based on the extant theory, the 
respondents’ likelihood to choose to use the system is 
promising and merits a large-scale evaluation study.  
5. Conclusions 
This study demonstrates a novel concept of an AI-
based VA-IA CDSS. Whereas AI-based CDSS, as 
well as systems with visual data presentation, albeit 
rather static, are not new [49], systems designed for AI 
analytics that are also composed of VA-IA 
components are quite rare [46]. Hence, the main 
contribution of this study is in presenting an actual 
implementation of design principles conjectured to 
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drive CDSS adoption, by placing the expert in the 
decision-making loop alongside the computer, 
facilitating an intelligence augmenting environment 
[50, 51]. Thus, this CDSS conceptualization addresses 
recent calls to harness AI, VA and human-computer 
collaboration for IA, leading to more effective and 
efficient healthcare processes and point of care 
decision making [33, 47]. Such systems are advocated 
to eventually leverage the huge amount of patient-
level healthcare data for precision care and more 
informed clinical decision making [52]. Moreover, it 
is believed that the collaborative nature of such 
systems is likely to alleviate barriers to CDSS 
adoption due to concerns about loss of autonomy and 
devaluation of expertise [53]. These hypotheses need 
to be evaluated by more experts, preferably via 
randomized experiments in varied clinical settings 
such as inpatient, ambulatory and emergency care, and 
with different groups of clinical specialties. 
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